Published in Diabetologia on August 03, 2017
The pharmacogenetics of metformin. Diabetologia (2017) 0.77
60 years of metformin use: a glance at the past and a look to the future. Diabetologia (2017) 0.75
The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care (1999) 16.79
Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res (2009) 6.74
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene (2008) 5.85
Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol (2002) 4.55
Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) (2010) 4.36
Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care (2010) 3.68
Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care (2012) 3.11
Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov (2012) 3.02
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One (2012) 2.84
Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila) (2011) 2.77
Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer (2008) 2.53
Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia (2012) 2.53
Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. Elife (2014) 2.48
Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature (2014) 2.27
Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol (2012) 2.22
Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One (2013) 2.10
Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos (2007) 1.97
Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat (2011) 1.90
Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila) (2010) 1.86
Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist (2012) 1.79
Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res (2010) 1.70
Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat (2012) 1.66
Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos (2007) 1.60
Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. Lancet Oncol (2016) 1.58
Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol (2013) 1.49
Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila) (2014) 1.38
OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proc Natl Acad Sci U S A (2014) 1.24
The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis. Diabetes Obes Metab (2014) 1.23
Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. Metabolism (2013) 1.12
Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial. Cancer (2014) 1.10
Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer. Cancer Med (2014) 1.10
Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies. Sci Rep (2015) 0.98
AMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell. Cancer Biol Ther (2015) 0.96
Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer. Cancer Invest (2014) 0.94
Metformin Is Associated With Slightly Reduced Risk of Colorectal Cancer and Moderate Survival Benefits in Diabetes Mellitus: A Meta-Analysis. Medicine (Baltimore) (2016) 0.90
A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer. Prostate Cancer Prostatic Dis (2014) 0.89
Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status. Circ Res (2016) 0.89
Measuring the biological effect of presurgical metformin treatment in endometrial cancer. Br J Cancer (2016) 0.88
Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study. Clin Breast Cancer (2012) 0.87
Metformin and prostate cancer mortality: a meta-analysis. Cancer Causes Control (2015) 0.86
Association between Metformin Therapy and Breast Cancer Incidence and Mortality: Evidence from a Meta-Analysis. J Breast Cancer (2015) 0.85
Metformin Targets Central Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers. Cell Metab (2016) 0.84
Metformin decreases IL-22 secretion to suppress tumor growth in an orthotopic mouse model of hepatocellular carcinoma. Int J Cancer (2014) 0.84
Metformin therapy associated with survival benefit in lung cancer patients with diabetes. Oncotarget (2016) 0.84
Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol (2016) 0.83
Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's esophagus. Clin Gastroenterol Hepatol (2014) 0.83
Correction of permeability with pore radius of tight junctions in Caco-2 monolayers improves the prediction of the dose fraction of hydrophilic drugs absorbed by humans. Pharm Res (2004) 0.83
Metformin use improves survival of diabetic liver cancer patients: systematic review and meta-analysis. Oncotarget (2016) 0.82
The effect of metformin on mortality following cancer among patients with diabetes. Cancer Epidemiol Biomarkers Prev (2014) 0.82
Metformin: historical overview. Diabetologia (2017) 0.81
Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer†. Ann Oncol (2015) 0.81
Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis (2015) 0.80
Repurposing old drugs to chemoprevention: the case of metformin. Semin Oncol (2015) 0.80
Cation-selective transporters are critical to the AMPK-mediated antiproliferative effects of metformin in human breast cancer cells. Int J Cancer (2016) 0.80
Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis. Oncotarget (2017) 0.78
Effects of metformin on survival outcomes of lung cancer patients with type 2 diabetes mellitus: a meta-analysis. Clin Transl Oncol (2015) 0.78
Systematic review and meta-analysis of the effect of metformin treatment on overall mortality rates in women with endometrial cancer and type 2 diabetes mellitus. Maturitas (2017) 0.78
Reduced colorectal cancer incidence in type 2 diabetic patients treated with metformin: a meta-analysis. Pharm Biol (2016) 0.77
Metformin use and the risk of colorectal adenoma: A systematic review and meta-analysis. J Gastroenterol Hepatol (2017) 0.76
Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial. Laryngoscope (2017) 0.76
Colon neoplasia in patients with type 2 diabetes on metformin: A meta-analysis. Eur J Intern Med (2016) 0.76